Split-Dosing Regimen Granted FDA Approval for Multiple Myeloma Treatment
February 12th 2019Daratumumab was first approved in November 2015 as the first and only CD38-directed antibody for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to both.
Read More